NEW YORK, June 21, 2022 – Behrman Capital, a private equity investment firm based in New York, today announced the sale of its portfolio company Emmes (the “Company”) to affiliates of New Mountain Capital. The transaction is expected to close…
Casimir Further Differentiates Emmes’ Industry-Leading Rare Disease Research Capabilities Rockville, MD, March 10, 2022 – Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company…
Third Add-on Acquisition Under Behrman’s Ownership Expands European Presence in Germany; Adds New Electronic Data Capture Tool to Enhance Real World Evidence Research Rockville, MD, December 21, 2021 – Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated…
Second Add-on Acquisition Under Behrman’s Ownership Further Expands Emmes’ European Footprint and Market-Leading Capabilities in Rare Diseases Rockville, MD, May 11, 2021 – Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public…
Transaction Expands Emmes’ BioPharma Effort and European Presence Rockville, MD – December 30, 2020 – The Emmes Company, LLC (“Emmes”), a full-service clinical research organization (CRO) dedicated to supporting the advancement of human health and biopharmaceutical innovation and a portfolio…
New York, March 11, 2019 – Behrman Capital (“Behrman”), a private equity investment firm based in New York and San Francisco, today announced that it has made a significant investment in The Emmes Corporation (“Emmes” or “the Company”). Financial terms…